№ files_lp_3_process_7_017735
File format: docx Character count: 2094 File size: 28 KB
Editorial submission letter presenting a retrospective comparative clinical study of branded and compounded semaglutide formulations for publication consideration in a peer-reviewed medical journal.
Date: November 17, 2025
Type of document: Cover letter
Manuscript title: Effectiveness, Adherence, and Safety of Branded Wegovy™ vs. Compounded Semaglutide + Cyanocobalamin (CSC)
Article type: Original Article
Journal: The Journal of Obesity and Metabolism
Author: Shanmugesh Raja, MS
Affiliation: University of California, San Francisco
Study design: Retrospective cohort study
Data source: De-identified telemedicine cohort
Interventions studied: FDA-approved semaglutide (Wegovy™) and compounded semaglutide + cyanocobalamin
Outcomes assessed: Weight-loss magnitude and milestones, treatment adherence and persistence, adverse event reporting
Regulatory context: FDA-approved semaglutide compared with compounded formulation
Conflict of interest disclosure: Confirmed disclosed
Prior publication status: Not previously published and not under consideration elsewhere
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
SEMAGLUTIDE, Solution for injection 2 mg in 1.5 mL pre-filled pen, Solution for injection 4 mg in 3 mL pre-filled pen, Ozempic®, Novo Nordisk Pharmaceuticals Pty Ltd
Year: 2019
Region / City: Australia
Topic: Type 2 Diabetes Mellitus Treatment
Document Type: Submission for PBS listing
Organization / Institution: Pharmaceutical Benefits Advisory Committee (PBAC)
Author: Novo Nordisk Pharmaceuticals Pty Ltd
Target Audience: Medical practitioners, healthcare providers
Period of Validity: Ongoing after approval in 2020
Approval Date: 1 July 2020
Date of Last Modification: 2021
Topics: Wegovy Cyanocobalamin SEMAGLUTIDE